Technical Trend and Momentum Analysis
Over the past week, Amrutanjan Health Care’s technical trend has deteriorated from mildly bearish to outright bearish, underscoring increased selling pressure. The daily moving averages have turned bearish, indicating that the stock’s short-term price action is under strain. This is further corroborated by the Bollinger Bands, which remain bearish on both weekly and monthly timeframes, suggesting sustained volatility and downward pressure.
The Moving Average Convergence Divergence (MACD) presents a nuanced picture. While the weekly MACD remains mildly bullish, hinting at some short-term positive momentum, the monthly MACD is bearish, signalling that the longer-term trend is weakening. This divergence between weekly and monthly MACD readings often points to a transitional phase where short-term rallies may be met with resistance from broader downtrends.
Relative Strength Index (RSI) readings add further complexity. The weekly RSI currently shows no clear signal, hovering in a neutral zone, whereas the monthly RSI is bullish, indicating that the stock may be oversold on a longer-term basis and could be poised for a rebound. However, the absence of a weekly RSI signal tempers optimism, suggesting that short-term momentum remains uncertain.
Price Action and Volatility
On 6 May 2026, Amrutanjan Health Care’s stock opened at ₹577.00, which was also its intraday high, before falling to a low of ₹531.70. The closing price of ₹533.50 represents a steep 7.54% drop from the previous close of ₹577.00. This sharp decline highlights the immediate bearish sentiment prevailing in the market.
Comparing the current price to the 52-week range, the stock is trading closer to its low of ₹490.00 than its high of ₹789.95, reinforcing the downward pressure it has faced over the past year. The stock’s year-to-date return of -20.15% significantly underperforms the Sensex’s -9.63% return over the same period, reflecting sector-specific or company-specific challenges.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Longer-Term Performance and Market Comparison
Amrutanjan Health Care’s performance over various time horizons reveals persistent underperformance relative to the broader market. Over the past year, the stock has declined by 23.24%, while the Sensex has fallen by a more modest 4.68%. Extending the view to three and five years, the stock’s returns of -11.03% and -15.20% respectively contrast sharply with the Sensex’s robust gains of 26.15% and 58.22% over the same periods.
Despite these setbacks, the stock has delivered a strong 10-year return of 141.79%, though this still trails the Sensex’s 204.87% gain, indicating that while the company has created value over the long term, recent years have been challenging.
Additional Technical Indicators
The Know Sure Thing (KST) indicator, a momentum oscillator, is bearish on both weekly and monthly charts, reinforcing the negative momentum. Dow Theory readings are mixed, with a mildly bullish weekly signal but no discernible monthly trend, suggesting short-term optimism may be offset by longer-term uncertainty.
On-Balance Volume (OBV) shows no clear trend on either weekly or monthly timeframes, indicating that volume flows have not decisively supported either buying or selling pressure recently. This lack of volume confirmation adds to the cautious outlook.
Mojo Score and Grade Revision
MarketsMOJO’s proprietary Mojo Score for Amrutanjan Health Care stands at 50.0, reflecting a neutral stance. The Mojo Grade has been downgraded from Buy to Hold as of 18 Nov 2025, signalling a reassessment of the stock’s risk-reward profile amid the evolving technical landscape. The company remains classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and sensitivity to sector-specific developments.
Considering Amrutanjan Health Care Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investor Takeaway and Outlook
Amrutanjan Health Care’s recent technical deterioration and price weakness warrant a cautious approach. The bearish signals from daily moving averages, Bollinger Bands, and KST indicators suggest that the stock may face continued downward pressure in the near term. However, the bullish monthly RSI and mildly bullish weekly MACD indicate potential for a medium-term recovery if positive catalysts emerge.
Investors should closely monitor the stock’s ability to hold above its 52-week low of ₹490.00 and watch for any improvement in volume trends that could signal renewed buying interest. Given the downgrade to a Hold rating and the mixed technical signals, a wait-and-watch stance may be prudent until clearer momentum emerges.
Comparatively, the stock’s underperformance relative to the Sensex over multiple timeframes highlights the importance of evaluating sector and company fundamentals alongside technical factors. For those seeking exposure to Pharmaceuticals & Biotechnology, exploring alternative small-cap opportunities with stronger technical profiles may be advisable.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
